专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2019048930A2 BACTERIOPHAGE FOR MODULATING INFLAMMATORY BOWEL DISEASE 审中-公开
公开(公告)号：WO2019048930A2
公开(公告)日：2019-03-14
申请号：PCT/IB2018/001128
申请日：2018-09-07
申请人： KEIO UNIVERSITY , BIOMX LTD. , YEDA RESEARCH AND DEVELOPMENT CO. LTD. AT THE WEITZMANN INSTITUTE OF SCIENCE
发明人： HONDA, Kenya , ATARASHI, Koji , NARUSHIMA, Seiko , ELINAV, Eran , SOREK, Rotem , KHABRA, Efrat , BEN DAVID, Hava , WEINSTOCK, Eyal , POLLOCK, Sarah , MUTIUHIN, Yulia , ZAK, Naomi
IPC分类号： A61K35/00
摘要： Disclosed herein are bacteriophage compositions and therapeutic uses thereof. The disclosure also relates to bacteriophage that are capable of lysing Klebsiella bacterial strains, e.g., strains that are associated with inflammatory bowel disease, and thereby capable of modulating disease.

2. 发明申请

WO2017138007A1 MICROBIOME-BASED DIAGNOSIS, PREDICTION AND TREATMENT OF RELAPSING OBESITY 审中-公开
标题翻译：基于微生物的诊断，预测和治疗肥胖的肥胖
公开(公告)号：WO2017138007A1
公开(公告)日：2017-08-17
申请号：PCT/IL2017/050187
申请日：2017-02-14
申请人： YEDA RESEARCH AND DEVELOPMENT CO. LTD. at the Weizmann Institute of Science
发明人： ELINAV, Eran , SEGAL, Eran
IPC分类号： C12Q1/68 , A61K35/741 , A23L33/135
CPC分类号： C12Q1/689 , A23L33/105 , A23L33/30 , A23V2002/00 , A61K31/00 , A61K35/74 , A23V2200/332 , A23V2250/2116
摘要： A method of analyzing the likelihood of weight regain in a subject who has reached a target weight by practicing a weight loss program is disclosed. The method comprises determining an amount or presence of at least one microbe and/or product thereof in the gut microbiome of the subject, wherein the amount of the at least one microbe is altered during a prior weight gain period of the subject to reach a level representative of an obese subject and further wherein the amount of the at least one microbe is retained at the level following the weight loss program, wherein the amount or presence of the at least one microbe or product thereof is predictive of weight regain.
摘要翻译：公开了通过实践减肥计划来分析已经达到目标体重的受试者的体重恢复可能性的方法。该方法包括确定受试者的肠道微生物组中至少一种微生物和/或其产物的量或存在，其中至少一种微生物的量在受试者的先前体重增加期期间改变以达到一定水平代表肥胖对象，并且进一步其中所述至少一种微生物的量保持在减重计划之后的水平，其中所述至少一种微生物或其产物的量或存在预测体重恢复。 >

3. 发明申请

WO2016185469A1 BACTERIAL POPULATIONS FOR PROMOTING HEALTH 审中-公开
标题翻译：促进健康的细菌人口
公开(公告)号：WO2016185469A1
公开(公告)日：2016-11-24
申请号：PCT/IL2016/050520
申请日：2016-05-17
申请人： YEDA RESEARCH AND DEVELOPMENT CO. LTD.
发明人： SEGAL, Eran , ELINAV, Eran
IPC分类号： A61P3/10 , A61K35/66 , A61K35/74 , A61P3/08
CPC分类号： A61K35/747 , A61K35/741 , A61K35/744 , A61K35/745 , A61K2300/00 , A61P3/08 , Y02A50/47 , Y02A50/473 , Y02A50/475
摘要： A method of improving the glucose response in glucose tolerant and intolerant subjects is provided. The method comprises providing to the subject probiotic compositions, or agents which specifically reduce bacterial species.
摘要翻译：提供了改善葡萄糖耐量和不耐受受试者的葡萄糖反应的方法。该方法包括向受试者提供益生菌组合物或特异性减少细菌物种的试剂。

4. 发明申请

WO2015166489A3 METHOD AND APPARATUS FOR PREDICTING RESPONSE TO FOOD 审中-公开
公开(公告)号：WO2015166489A3
公开(公告)日：2015-11-05
申请号：PCT/IL2015/050439
申请日：2015-04-28
申请人： YEDA RESEARCH AND DEVELOPMENT CO. LTD.
发明人： SEGAL, Eran , ELINAV, Eran
IPC分类号： G06F19/00
摘要： Method of predicting a response of a subject to food is disclosed. The method comprises: selecting a food to which a response of the subject is unknown; accessing a first database having data describing the subject but not a response of the subject to the selected food; accessing a second database having data pertaining to responses of other subjects to foods, the responses of the other subjects including responses of at least one other subject to the selected food or a food similar to said selected food; and analyzing the databases based on the selected food to estimate the response of the subject to the selected food.

5. 发明申请

WO2021038569A1 TREATMENT OF BACTERIAL VAGINOSIS 审中-公开
公开(公告)号：WO2021038569A1
公开(公告)日：2021-03-04
申请号：PCT/IL2020/050937
申请日：2020-08-27
申请人： YEDA RESEARCH AND DEVELOPMENT CO. LTD. , HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
发明人： ELINAV, Eran , COHEN, Yotam , LEV-SAGIE, Achinoam , GOLDMAN-WOHL, Debra
IPC分类号： A61K35/00 , A61P31/04
摘要： A method of treating bacterial vaginosis in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of a composition which comprises between three and twenty species of bacteria or a secretion thereof, wherein at least 70 % of the bacteria of the composition are of the species Lactobacillus crispatus, thereby treating the bacterial vaginosis.

6. 发明申请

WO2016174677A1 USE OF MICROBIAL METABOLITES FOR TREATING DISEASES 审中-公开
标题翻译：使用微生物代谢物治疗疾病
公开(公告)号：WO2016174677A1
公开(公告)日：2016-11-03
申请号：PCT/IL2016/050442
申请日：2016-04-27
申请人： YEDA RESEARCH AND DEVELOPMENT CO. LTD.
发明人： ELINAV, Eran , SEGAL, Eran
IPC分类号： C12Q1/02 , C12Q1/04 , C12Q1/06 , C12Q1/24 , A61K31/417
CPC分类号： C12Q1/689 , A61K31/132 , A61K31/185 , A61K31/417 , A61P1/00 , G01N33/6893 , G01N2800/065 , G01N2800/52 , A61K2300/00
摘要： A method of determining the therapeutic effect of an agent, such as a metabolite, comprising: (a) exposing a pathological microbiome to the agent; and (b) comparing the signature of the pathological microbiome following the exposing with a reference signature of a healthy microbiome, wherein when the signature of the microbiome is statistically significantly similar to the healthy microbiome reference signature, it is indicative that the agent has a therapeutic effect on the microbiome. The agent may be provided to a subject having a pathological microbiome once it has been classified as therapeutic.
摘要翻译：确定药剂如代谢物的治疗效果的方法，包括：（a）将病理微生物组合物暴露于所述药剂; 和（b）将暴露后的病理微生物组合的签名与健康微生物组合的参考标记进行比较，其中当所述微生物组的标记在统计学上显着类似于健康的微生物参考标记时，表明所述试剂具有治疗对微生物的影响。一旦将其分类为治疗剂，可将药剂提供给具有病理性微生物组织的受试者。

7. 发明申请

WO2008095141A2 REDIRECTED, GENETICALLY-ENGINEERED T REGULATORY CELLS AND THEIR USE IN SUPPRESSION OF AUTOIMMUNE AND INFLAMMATORY DISEASE 审中-公开
标题翻译：重定向，遗传工程化的T细胞及其在抑制自身免疫和炎症疾病中的应用
公开(公告)号：WO2008095141A2
公开(公告)日：2008-08-07
申请号：PCT/US2008/052724
申请日：2008-01-31
申请人： YEDA RESEARCH AND DEVELOPMENT CO. LTD. , GERAGHTY, Erin , ESHHAR, Zelig , ELINAV, Eran
发明人： ESHHAR, Zelig , ELINAV, Eran
IPC分类号： C12N5/00
CPC分类号： C12N5/0636 , A61K39/0008 , A61K39/0011
摘要： A redirected Treg cell is endowed with specificity toward a selected target antigen or ligand. The cell contains a chimeric receptor polypeptide that is expressed in a single, continuous chain, with an extracellular recognition region displayed on the surface of the cell, a transmembrane region and an intracellular signaling region. The extracellular recognition region is specific for the selected target antigen or ligand. The intracellular signaling region includes a combination of T-cell signaling polypeptide moieties, which combination, upon binding of the extracellular recognition region to the selected target antigen or ligand, triggers activation of the redirected Treg cells to cause suppression of T-cell mediated immunity. Such redirected Treg cells may be used to suppress undesired activity of T effector cells thereby mediating an immune or inflammatory response. They are particularly useful in treating T effector cell-mediated diseases, such as inflammatory bowel disease, transplant rejection and GVH disease.
摘要翻译：重定向的Treg细胞被赋予对所选靶抗原或配体的特异性。细胞含有在单个连续链中表达的嵌合受体多肽，细胞外识别区域显示在细胞表面，跨膜区和胞内信号传导区。细胞外识别区域对于所选择的靶抗原或配体是特异性的。细胞内信号传导区域包括T细胞信号传导多肽部分的组合，当细胞外识别区域与所选择的靶抗原或配体结合时，其组合触发重定向的Treg细胞的激活以引起T细胞介导的免疫的抑制。这种重定向的Treg细胞可以用于抑制T效应细胞的不期望的活性，从而介导免疫或炎症反应。它们特别可用于治疗T效应细胞介导的疾病，例如炎性肠病，移植排斥和GVH疾病。

8. 发明申请

WO2020012467A3 PERSON-SPECIFIC ASSESSMENT OF PROBIOTICS RESPONSIVENESS 审中-公开
公开(公告)号：WO2020012467A3
公开(公告)日：2020-01-16
申请号：PCT/IL2019/050760
申请日：2019-07-08
申请人： YEDA RESEARCH AND DEVELOPMENT CO. LTD. , THE MEDICAL RESEARCH, INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER
发明人： SEGAL, Eran , ELINAV, Eran , HALPERN, Zamir
IPC分类号： G16B10/00 , G16H20/60 , G16H50/30 , C12Q1/689 , A23L33/135 , A61K35/741 , G16H10/40 , G16H50/20
摘要： A method of assessing whether a candidate subject is suitable for probiotic treatment is disclosed. The method comprises determining a signature of the gut microbiome of the candidate subject, wherein when the signature of the microbiome of the candidate subject is statistically significantly similar to a signature of a gut microbiome of a control subject known to be responsive to probiotic treatment, it is indicative that the subject is suitable for probiotic treatment.

9. 发明申请

WO2020012467A2 PERSON-SPECIFIC ASSESSMENT OF PROBIOTICS RESPONSIVENESS 审中-公开
公开(公告)号：WO2020012467A2
公开(公告)日：2020-01-16
申请号：PCT/IL2019/050760
申请日：2019-07-08
申请人： YEDA RESEARCH AND DEVELOPMENT CO. LTD. , THE MEDICAL RESEARCH, INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER
发明人： SEGAL, Eran , ELINAV, Eran , HALPERN, Zamir
IPC分类号： G16B10/00 , G16H20/60 , G16H50/30 , C12Q1/689 , A23L33/135 , A61K35/741 , G16H10/40 , G16H50/20
摘要： A method of assessing whether a candidate subject is suitable for probiotic treatment is disclosed. The method comprises determining a signature of the gut microbiome of the candidate subject, wherein when the signature of the microbiome of the candidate subject is statistically significantly similar to a signature of a gut microbiome of a control subject known to be responsive to probiotic treatment, it is indicative that the subject is suitable for probiotic treatment.

10. 发明申请

WO2019048930A3 BACTERIOPHAGE FOR MODULATING INFLAMMATORY BOWEL DISEASE 审中-公开
公开(公告)号：WO2019048930A3
公开(公告)日：2019-03-14
申请号：PCT/IB2018/001128
申请日：2018-09-07
申请人： KEIO UNIVERSITY , BIOMX LTD. , YEDA RESEARCH AND DEVELOPMENT CO. LTD. AT THE WEITZMANN INSTITUTE OF SCIENCE
发明人： HONDA, Kenya , ATARASHI, Koji , NARUSHIMA, Seiko , ELINAV, Eran , SOREK, Rotem , KHABRA, Efrat , BEN DAVID, Hava , WEINSTOCK, Eyal , POLLOCK, Sarah , MUTIUHIN, Yulia , ZAK, Naomi
IPC分类号： A61K9/00 , A61K35/76 , C12N7/00
摘要： Disclosed herein are bacteriophage compositions and therapeutic uses thereof. The disclosure also relates to bacteriophage that are capable of lysing Klebsiella bacterial strains, e.g., strains that are associated with inflammatory bowel disease, and thereby capable of modulating disease.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式